Quoting the release
PYC Therapeutics has completed a key translational milestone for its RNA platform by determining safe and well tolerated doses of its co-lead drug candidate in Non-Human Primates (monkeys)The results represent a major step towards first in-human clinical studies for thisprogram - the first potential therapy for patients with Retinitis Pigmentosa type 11 that addresses the underlying cause of the disease
pretty happy with that - now what will Mr market think of this?
Ann: Successful Completion of Key Translational Milestone, page-9
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.8¢ |
Change
0.003(1.28%) |
Mkt cap ! $933.2M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.5¢ | 19.8¢ | $488.4K | 2.417M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 51122 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 655254 | 7 |
View Market Depth
| Last trade - 10.48am 16/10/2024 (20 minute delay) ? |
| PYC (ASX) Chart |